Novel therapeutic targets in Helicobacter pylori.
The failure of current regimens to treat the gastric pathogen Helicobacter pylori is a growing problem. Responsible for gastritis and peptic ulcer disease, and designated as a Class 1 carcinogen, its presence in up to 90% of the population of the developing world makes its treatment a primary concern. The use of genomic, proteomic and transcriptomic data to determine essential gene products as targets for novel therapeutic agents is of key interest in this research. This review describes how such data can be obtained, evaluated and eventually used as a basis for the development of both vaccine and novel anti-helicobacter agents. It indicates both past successes and possible new avenues to exploit the increased availability of such data, whilst also examining the limitations of such approaches.